Clinical Trials
6
Trial Phases
2 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
- Conditions
- Advanced Cancer
- Interventions
- Drug: SGX523 Capsules
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- SGX Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00607399
- Locations
- 🇺🇸
Scottsdale Healthcare, Scottsdale, Arizona, United States
🇺🇸Premiere Oncology, Arizona, Scottsdale, Arizona, United States
Safety Study of SGX523, a Small Molecule Met Inhibitor, to Treat Solid Tumors
- Conditions
- Advanced Cancer
- Interventions
- Drug: SGX523 Capsules
- First Posted Date
- 2008-02-05
- Last Posted Date
- 2008-07-24
- Lead Sponsor
- SGX Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT00606879
- Locations
- 🇺🇸
Premier Onocology, California, Santa Monica, California, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
Study for Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)
- Conditions
- Leukemia, Myeloid, Acute
- First Posted Date
- 2005-08-12
- Last Posted Date
- 2006-11-03
- Lead Sponsor
- SGX Pharmaceuticals, Inc.
- Target Recruit Count
- 211
- Registration Number
- NCT00129948
- Locations
- 🇺🇸
Scripps Clinic, LaJolla, California, United States
🇺🇸USC-Norris Neuro-Oncology Program, Los Angeles, California, United States
🇺🇸UCSD Moores Cancer Center, San Diego, California, United States
Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML)
- Conditions
- Acute Myelogenous Leukemia
- First Posted Date
- 2005-03-01
- Last Posted Date
- 2008-01-17
- Lead Sponsor
- SGX Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00104468
- Locations
- 🇺🇸
Cornell Medical College, New York Presbyterian, New York, New York, United States
🇺🇸MD Anderson, Houston, Texas, United States
Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Solid Tumors
- Conditions
- Neoplasms
- First Posted Date
- 2005-02-25
- Last Posted Date
- 2006-11-03
- Lead Sponsor
- SGX Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00104286
- Locations
- 🇺🇸
The Sydney Kimmel Comprehensive Cancer Center at John Hopkins, Baltimore, Maryland, United States